

### Abstract

The present inventors have carried out intensive screening of a new type compound which inhibits the P<sub>2</sub>X<sub>2/3,3</sub> receptor and found as a result that minodronic acid as a 5 bisphosphonate having bone resorption inhibitory action shows excellent P<sub>2</sub>X<sub>2/3,3</sub> receptor inhibitory action and can be used as a preventive or therapeutic agent for various pains, thus accomplishing the invention. That is, the invention relates to a P<sub>2</sub>X<sub>2/3,3</sub> receptor inhibitor, 10 particularly an analgesic, which comprises minodronic acid or a salt thereof as the active ingredient.

Since the "P<sub>2</sub>X<sub>2/3</sub> and/or P<sub>2</sub>X<sub>3</sub> receptor inhibitor" of the invention inhibits the function of P<sub>2</sub>X<sub>2/3,3</sub> receptor known as a molecule which is concerned in various pains 15 consisting of nociceptive pain, inflammatory pain and neurogenic pain, it is useful for the prevention or treatment of various pains in which the P<sub>2</sub>X<sub>2/3,3</sub> receptor is concerned in the pain transduction.